Response to anti-angiogenesis: an ever changing feature.
Anti-angiogenic drugs have gained international approval for the therapy of advanced breast, lung, colo-rectal, kidney and central nervous system cancer. However, the clinical benefit associated with the use of these drugs has been so far limited. This review discuss the possible rational developments of a new generation anti-angiogenic drugs. Since most of the biological and clinical activity of the currently available generation of anti-angiogenic drugs targets VEGF and its related pathways, it seems relevant to (1) better understand mechanisms of resistance and/or escape from anti-VEGF and (2) identify and validate vascular targets complementary to anti-VEGF.